RxDoctor Payments Data

Mohamad Bourji, MD

Cardiovascular Disease · Florence, SCNPI 1336300045

Payments from drug & device makers

$1,101in general payments, 2019–2025

Across 38 payments — averaging $28.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$237
  • AstraZeneca$181
  • Irhythm Technologies, Inc.$154
  • Boston Scientific$138
  • Biotronik Inc.$96
  • Novartis$84
  • plus $209 from 8 others

What the payments were for

  • Food & beverage$1,08799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,101 in reported general payments places this provider in the 25th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$251,566
Medicare patients
2,024
Services billed
5,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban330$321,604
EntrestoSacubitril/Valsartan161$138,096
MultaqDronedarone Hcl71$73,702
XareltoRivaroxaban83$71,299
Repatha SureclickEvolocumab49$64,070
JardianceEmpagliflozin49$38,389
Repatha PushtronexEvolocumab44$37,237
Praluent PenAlirocumab25$33,334
BrilintaTicagrelor48$30,929
FarxigaDapagliflozin Propanediol42$30,293
Ranolazine ErRanolazine158$11,001
Bumetanide243$6,442
Metoprolol Succinate419$4,991
Midodrine Hcl94$4,714
Atorvastatin Calcium419$4,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$84$138,096161 claims
Johnson & JohnsonXarelto$41$71,29983 claims
AstraZenecaBrilinta, Farxiga$181$61,22390 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →